Opinion|Videos|January 22, 2025

Overview of the DESTINY-Breast06 Study

Panelists discuss the results and implications of the DESTINY-Breast06 study, highlighting the efficacy of trastuzumab deruxtecan in patients with HER2-positive breast cancer previously treated with multiple lines of therapy.


Latest CME